Drugs / TGRX-678
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06986772 | Jul → Aug 2025 | chronic myeloid leukemia | Shenzhen TargetRx Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06697899 | Nov 2024 → Jan 2025 | chronic myeloid leukemia | Shenzhen TargetRx Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06088888 | Jul 2024 → Mar 2027 expected | chronic myeloid leukemia | Shenzhen TargetRx Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05434312 | Mar 2021 → Mar 2026 overdue | chronic myeloid leukemia | Shenzhen TargetRx Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06453902 | Jul 2024 → Jun 2026 overdue | leukemia, myeloid, accelerated-phase | Shenzhen TargetRx Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07489755 | Apr 2026 → May 2030 expected | chronic myeloid leukemia | Shenzhen TargetRx Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TGRX-678 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06697899 ↗ |
| Action | Inhibit | “TGRX-678, a tyrosine kinase inhibitor indicated for treatment of chronic myeloid leukemia” NCT06986772 ↗ |
| Route | Oral | “TGRX-678 tablets orally” NCT05434312 ↗ |